1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAlzheimer's Clinical Trials Consortium (ACTC) R01 Notice of Funding Opportunity (NOFO) is sponsored by National Institute on Aging (NIA). Supports clinical trials for Alzheimer's disease and related dementias, including tau-related studies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials Agency: National Institutes of Health Assistance Listings: 93. 866 -- Aging Research Last Updated: May 13, 2026 View version history on Grants.
gov The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.
Working with the ACTC is a collaborative venture between the applicant, NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. The work of this NOFO will enable the testing of interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the R01 activity code.
Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this NOFO.
For-profit organizations other than small businesses Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Private institutions of higher education Independent school districts Public and state institutions of higher education Public and Indian housing authorities Federally recognized Native American tribal governments Grantor contact information National Institute on Aging (NIA) No documents are currently available.
Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments. Confirm the full requirements in the official notice before applying.
Alzheimer's Clinical Trials Consortium (ACTC) R01 Notice of Funding Opportunity (NOFO) is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article